Literature DB >> 26114842

Centralized Reading Center Improves Quality in a Real-World Setting.

Sharon M Hudson, Richard Contreras, Michael H Kanter, Stephen J Munz, Donald S Fong.   

Abstract

BACKGROUND AND
OBJECTIVE: Diabetic retinopathy (DR) screening is standard of care, but its utility diminishes unless high quality is maintained. This project describes the improvement in diagnostic accuracy achieved at a large health maintenance organization by implementing a centralized reading center. PATIENTS AND METHODS: Data were extracted from the electronic health records of patients with diabetes who underwent DR screening between January 1, 2009, and December 31, 2013, at 13 medical centers. Certified ophthalmic assistants and technicians were trained to read DR images under the supervision of a retinal specialist. This program was pilot-tested prior to full implementation.
RESULTS: DR prevalence among the 13 centers in 2009 was 10.1%, far below the national average. After implementation, prevalence increased to 22.1%. The program also resulted in improved access to follow-up.
CONCLUSION: The results demonstrate the value of a reading center in decreasing diagnostic error and achieving other improvements in a real-world setting. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Year:  2015        PMID: 26114842     DOI: 10.3928/23258160-20150610-05

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  2 in total

1.  Two-Year Incidence of Retinal Intervention in Patients With Minimal or No Diabetic Retinopathy on Telemedicine Screening.

Authors:  Bobeck S Modjtahedi; Christos Theophanous; Stephan Chiu; Tiffany Q Luong; Natasha Nguyen; Donald S Fong
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

Review 2.  Clinical Components of Telemedicine Programs for Diabetic Retinopathy.

Authors:  Mark B Horton; Paolo S Silva; Jerry D Cavallerano; Lloyd Paul Aiello
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.